Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
DELRAY BEACH - PetMed Express, Inc. (NASDAQ:PETS), the parent company of PetCareRx, announced Tuesday it will miss the extended deadline to file its annual 10-K report for the fiscal year ended March 31, 2025. The company’s stock, which has declined over 31% in the past six months according to InvestingPro data, currently appears undervalued based on comprehensive Fair Value analysis.
The delay stems from an ongoing investigation by the company’s Audit Committee following anonymous whistleblower reports concerning revenue recognition practices, a customer coupon promotion, and the company’s culture and control environment.
According to the company’s statement, the whistleblower allegations specifically relate to "the timing of revenue recognition with respect to certain autoship orders" in the fourth quarter, a "$50 coupon promotion to customers and its potential impact on company key-performance indicators regarding new customers," and concerns about the company’s culture.
The pet healthcare retailer has engaged external legal counsel and advisors to investigate these reports. While the investigation continues with no conclusions reached, PetMeds stated it "does not currently expect that this investigation will have a material impact on its previously announced preliminary financial results."
The company had initially filed for an extension on June 16, which provided until July 1 to submit its annual report. PetMeds indicated it is "working diligently to complete its review and file the 2025 Form 10-K as soon as practicable."
Founded in 1996, PetMed Express operates as an online pharmacy licensed across all 50 states, offering pet pharmaceuticals and health products through its PetMeds and PetCareRx brands. For deeper insights into PETS’s financial health, valuation metrics, and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
The information in this article is based on a company press release statement.
In other recent news, PetMed Express has reported preliminary fourth-quarter sales between $51.1 million and $53.1 million, a notable decline from the $66.5 million reported in the same period last year. The company also anticipates a quarterly net loss ranging from $9.9 million to $10.4 million, compared to a $5.0 million loss in the prior year. For the fiscal year ending March 31, 2025, PetMeds expects sales between $231.6 million and $233.6 million, with an annual net loss estimated between $4.5 million and $5.0 million. The company has delayed its annual report filing and expects to submit it by July 1, 2025. In a strategic move, PetMed Express has partnered with Dutch, a virtual veterinary care provider, to enhance pet healthcare accessibility. Morgan Stanley has adjusted its outlook on PetMed Express, reducing the price target from $3.50 to $3.20 while maintaining an Underweight rating. Additionally, PetMed Express announced the appointment of Peter Batushansky to its Board of Directors, succeeding Dr. Gian Fulgoni, who will retire at the 2025 annual shareholders’ meeting. The company continues to undergo leadership changes, aiming to drive shareholder value and expand its online pet pharmacy business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.